Suppr超能文献

脂质体剂型胞磷胆碱滴眼液治疗开角型青光眼对视功能和视觉通路神经传导的增强作用:一项初步电功能研究。

Enhancement of Retinal Function and of Neural Conduction Along the Visual Pathway Induced by Treatment with Citicoline Eye Drops in Liposomal Formulation in Open Angle Glaucoma: A Pilot Electrofunctional Study.

机构信息

IRCCS-Fondazione Bietti, Rome, Italy.

Istituto di Ricerca Neuroftalmologia, Rome, Italy.

出版信息

Adv Ther. 2019 Apr;36(4):987-996. doi: 10.1007/s12325-019-0897-z. Epub 2019 Feb 21.

Abstract

INTRODUCTION

To evaluate the retinal function and the relative neural conduction along the visual pathway after treatment with citicoline in liposomal formulation (CLF) eye drops in patients with open angle glaucoma (OAG).

METHODS

Twelve OAG patients (mean age ± standard deviation 52.58 ± 11.39 years, intraocular pressure < 18 mmHg under topical hypotensive treatment, Humphrey field analyzer mean deviation - 4.49 ± 2.46 dB) were enrolled. Only one eye of studied patients was treated with CLF eye drops (OMK1-LF, Omikron Italia, 3 drops/day) (CLF group, 12 eyes) over a period of 4 months. In CLF eyes, pattern electroretinogram (PERG), visual evoked potentials (VEP), and visual field test were assessed at baseline and at the end of treatment (month 4).

RESULTS

After treatment with CLF eye drops, a significant increase of PERG P50-N95 amplitude and a significant shortening of VEP P100 implicit time were found. In CLF eyes, the shortening of VEP P100 implicit time was significantly correlated with the increase of PERG P50-N95 amplitude.

CONCLUSION

Data from this pilot study suggest that treatment with CLF eye drops induces an enhancement of the retinal bioelectrical responses (increase of PERG amplitude) with a consequent improvement of the bioelectrical activity of the visual cortex (shortening of VEP implicit time).

FUNDING

Omikron Italia S.r.l. and Opko Health Europe.

摘要

简介

评估载脂体制剂胞磷胆碱(CLF)滴眼剂治疗开角型青光眼(OAG)患者后的视网膜功能和视觉通路的相对神经传导。

方法

纳入 12 名 OAG 患者(平均年龄±标准差 52.58±11.39 岁,局部降压治疗下眼压<18mmHg,Humphrey 视野分析仪平均偏差-4.49±2.46dB)。仅研究患者的一只眼接受 CLF 滴眼剂(OMK1-LF,Omikron Italia,3 滴/天)(CLF 组,12 只眼)治疗 4 个月。在 CLF 眼中,基线和治疗结束时(第 4 个月)评估图形视网膜电图(PERG)、视觉诱发电位(VEP)和视野检查。

结果

在 CLF 滴眼剂治疗后,PERG P50-N95 振幅显著增加,VEP P100 潜伏期显著缩短。在 CLF 眼中,VEP P100 潜伏期缩短与 PERG P50-N95 振幅增加显著相关。

结论

这项初步研究的数据表明,CLF 滴眼剂治疗可诱导视网膜生物电反应增强(PERG 振幅增加),从而改善视觉皮层的生物电活动(VEP 潜伏期缩短)。

资助

Omikron Italia S.r.l. 和 Opko Health Europe。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验